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Risk factors associated with infection of
blood-borne virus among people who used
methamphetamine
Yilin Cai1, Zheng Dai2* , Sijin Wen1 and Ruchi Bhandari2
Abstract
Background: The surge of methamphetamine use has been a complicating factor compounding the steeply
increasing number of drug overdose deaths in the U.S. Infection from blood-borne viruses including hepatitis B
virus (HBV), hepatitis C virus (HCV) and HIV, related to methamphetamine use continue to grow. This study aims to
examine the risk factors associated with HBV, HCV and HIV among people who used methamphetamine.
Methods: People who ever used methamphetamine were identified from five National Health and Nutrition
Examination Survey (NHANES) cohorts, 2007 to 2016. The outcome was either positive or negative for blood-borne
viruses as identified from laboratory tests. Weighted statistics for the combined ten years of data were calculated by
multiplying the weighted variable for laboratory measurements by 0.2. We examined the association of sexual
activities (sexual partners, sexual identity), drug use behaviors (poly-drug use, injection drug use, frequency of drug
use, age started using methamphetamine), demographics, and socio-economic status with blood-borne viruses
using bivariate and multivariable logistic regression models.
Results: There were 1132 participants representing approximately 11,996,319 persons who ever used
methamphetamine in the U.S. Blood-borne viruses’ positive rate was 13.0 per 100,000. Multivariable logistic
regression analyses showed significant associations of blood-borne infections with age 40–49 years (vs. age 20–29
years, adjusted odds ratio 4.77, 95% CI 1.11–20.55), age 50–59 years (vs. age 20–29 years, 10.25, 2.40–43.82), living
within poverty index 1–1.9 (vs. poverty index > = 2, 2.55; 1.19–5.49), living below the poverty threshold (vs. poverty
index > = 2, 2.55; 1.11–5.86), having lower than high school education (vs. equal or higher than high school
education, 3.13; 1.51–6.46), sexual identity as other than heterosexual (vs. heterosexual, 5.60; 1.72–18.28), using
methamphetamine and heroin and cocaine (vs. using methamphetamine alone, 4.24; 1.06–16.92), injection drug
use (vs. no injection drug use, 3.15; 1.61–6.16), and started using methamphetamine at age above 25 (vs. started
using methamphetamine at age between 10 and 17, 2.09; 1.01–4.35).
Conclusions: Among people who use methamphetamine, those who use polysubstance, or who inject substances,
are in urgent need for vaccination and interventions to avoid further harm from blood borne infections.
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Background
Methamphetamine-related overdose has been increasing
across the United States (U.S.) for the past several years
[1]. According to the Centers for Disease Control and
Prevention (CDC) data, the overdose death rates of
psychostimulants with abuse potential, which primarily
include methamphetamine and other drugs such as am-
phetamine and methylphenidate, had tripled between
2016 and 2017 [2]. Provisional data from CDC indicates
that deaths involving psychostimulants continued to
increase in 2018, despite a drop in overall overdose
deaths observed at the same time [3]. People who use
methamphetamine also have elevated risks of nonfatal
harms, including mental health disorders [4], violent and
aggressive behavior [4], risky sexual behavior [4], sexu-
ally transmitted infection [5], harm to a fetus, and infec-
tion of blood-borne viruses (BBVs) [4, 6]. The pathogens
of primary concern for blood-borne infectious diseases
are the human immunodeficiency virus (HIV), hepatitis
B virus (HBV), and hepatitis C virus (HCV) [7].
Methamphetamine use has been strongly associated
with many outbreaks of blood-borne infections. Of the
HBV patients identified in the 2003 HBV outbreak in
Natrona County, Wyoming, 88% reported injecting
methamphetamine [8]. Methamphetamine use is preva-
lent among people living with HIV and AIDS, particu-
larly among men who have sex with men in the U.S. [9].
In the 2014 HIV outbreak in Scott County, Indiana, 22%
of the patients reported injecting methamphetamine
[10]. A study characterizing methamphetamine use and
HIV serological status in San Diego found that 54% of
the people who used methamphetamine were HIV posi-
tive [11]. Another study examined risk factors associated
with HBV infections among people who used metham-
phetamine [12]. A prospective cohort study conducted
in Canada determined that injecting methamphetamine
predicted HCV infection among young, street-involved
persons with injection drug use (IDU) [13].
Other than injection, methamphetamine use through
smoking, swallowing, or snorting also increases risk of
blood-borne infections by negatively affecting judgment
and triggering risky behaviors (e.g., unprotected sex)
[14]. In addition to that, it is suggested that long-time
methamphetamine use is associated with bleeding gums
[15] and increasing risk of blood-borne infections
through oral sex among the sexually active population.
Fatal and nonfatal harms caused by rapidly increasing
methamphetamine use are further compounded by exist-
ing opioid crisis, described by some scholars as “twin ep-
idemics” [16]. Polysubstance use, such as co-occurring
use of prescription opioids, synthetic opioids other than
methadone, heroin, cocaine, or methamphetamine is
now commonplace [1, 17, 18]. Specifically, in 2017,
opioids were involved in over half of the 10,333
psychostimulant-related deaths [1]. Deaths involving
opioids and methamphetamine significantly increased by
14% between July 2017 and June 2018 [18]. People prefer
to use multiple substances for various reasons: (a) to ex-
perience the synergistic effect; (b) to enhance the bene-
fits of each substance; (c) to overcome dysphoria and
manage withdrawal symptoms; (d) to experiment; (e) to
avail cheaper substances; (f) to balance the stimulation
from methamphetamine with sedation from opioid/her-
oin [19, 20]. However, since heroin, fentanyl, and meth-
amphetamine are all short-acting substances, persons
with IDU tend to inject more frequently to stay “high”.
The combined injection of methamphetamine and
opioids, or sequential use of methamphetamine after
opioids is associated with an increased number of injec-
tions and increased probability of the reuse of syringes,
thus, leading to elevated risk of BBVs [21–23].
Under this landscape of increasing polysubstance use,
it is not clear how methamphetamine use affects the
overall likelihood of blood-borne infections. A dynamic
model investigating the excess risk of HIV and HCV in-
fections among people who inject stimulants estimated
that a median of 5–10% of new HIV and 3–7% of new
HCV infections in the following year could each be at-
tributed to a 10% increase in the prevalence of stimulant
injection use [4]. Another recent study found that
women, poverty, IDU, and HCV infection were associ-
ated with increased risk of HBV infection among people
who use methamphetamine [12]. CDC and a few state
health departments have developed vulnerability assess-
ment tools to identify counties at high risk of HIV and
HCV; however, these tools do not include HBV [21, 24].
To date, no studies have used national data to examine
factors associated with overall likelihood of positive BBV
test results among people who use methamphetamine.
This study aims to examine risk factors associated with
positive BBV test results among people who use meth-
amphetamine in the National Health and Nutrition
Examination Survey (NHANES). Findings from this
study will identify vulnerable sub-population groups that
are susceptible to infections from BBVs.
Methods
Study data
The study population was identified from five NHANES
cohorts from 2007 to 2016. Conducted by the National
Center for Health Statistics (NCHS), NHANES is a con-
tinuous cross-sectional survey with data released biannu-
ally and is effective in determining the prevalence of
major diseases and associated risk factors among adults
and children in the U.S. [25, 26]. The NHANES data is
rich and unique in two ways. First, it combines informa-
tion collected from both interviews and physical exami-
nations that are necessary to answer the research
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questions. The interviews include demographics, socio-
economic status, drug use information, and health-
related questions; and the physical examinations include
medical measurements and results of laboratory tests.
Second, each survey cycle examines a nationally repre-
sentative sample, and findings from the study are
generalizable to the U.S. Further details are described
elsewhere [26].
Study population and sampling procedure
The study population comprised people who reported
methamphetamine use in their lifetime. We chose to use
the lifetime methamphetamine use (DUQ330 - ever used
methamphetamine) over the most recent methampheta-
mine use (DUQ350 - last time used methamphetamine)
because the latter variable has had up to 95% of data
missing. The flow chart in Fig. 1 illustrates the process
of case selection. The study included anyone who com-
pleted testing for any of the three sets of tests including
HBV, HCV and HIV, and also answered “yes” to both
questions “ever used cocaine/heroin/methamphetamine”
and “ever used methamphetamine”. The study excluded
anyone whose age was not between 20 and 59 years as
they were not eligible to answer drug use questions.
Data sources
The primary outcome measure was positive/negative de-
tection of any of the three BBVs (HBV, HCV, and HIV)
which were determined according to the results of a set
of serological tests. Three HBV serological markers were
tested in the NHANES study: antibody to hepatitis B
core antigen (anti-HBc), hepatitis B surface antigen
(HBsAg), and antibody to hepatitis B surface antigen
(HBsAb) [27]. The presence of HBsAg for at least six
months indicate a chronic HBV infection [28]. Positive
HBV detection was defined as a positive result of anti-
HBc; while negative HBV detection was defined as
negative for all HBV serological markers including anti-
HBc, HBsAg and HBsAb. Indeterminate serological test
results were coded as negative since we used a conserva-
tive definition to determine positive detection. The
HBsAg is tested only when the anti-HBc test is positive.
Participants who were HBsAb positive but anti-HBc
negative and HBsAg negative were not considered as a
population at risk of HBV infection, but susceptible to
HIV and HCV.
Two HCV markers were tested: hepatitis C antibody
and hepatitis C RNA [29]. The hepatitis C RNA test is
only conducted when the hepatitis C antibody test is
positive. Current HCV infection was indicated by both
hepatitis C antibody and RNA being positive. Chronic
HCV infection was defined as hepatitis C RNA positive
six months after an acute infection. Positive HCV detec-
tion was defined as a positive result for both hepatitis C
antibody and hepatitis C RNA, while negative HCV de-





20 to 59 years old
n = 18,816








Exclude: n = 1,878
Did not complete medical exam
Exclude: n = 29,894
Age less than 20 or over 59 years
Exclude: n = 15,821
Answered ‘no’ to ever using cocaine/heroin/ 
methamphetamine
(n = 13,330) & missing (n = 2,491)
Exclude: n = 1,863
Answered ‘no’ to ever using Methamphetamine
(n = 1,861) & missing (n = 2)
Fig. 1 The Flow Chart of Study Case Selection
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antibody. Those with a positive antibody HCV test, but a
missing RNA test, were also considered negative. Simi-
larly, indeterminate serological test results were coded as
negative.
Two HIV serological markers were tested: HIV-1 and
HIV-2 antibody [30]. Specimens were initially tested by
a combo set of HIV-1/2 Enzyme Immunoassay (EIA),
and then repeated reactive specimens are tested with
HIV-1/2 supplemental assay. Positive HIV detection was
defined as positive results from the two rounds of tests.
If EIA is positive but following supplemental tests are
not positive (e.g., negative, indeterminate), a confirma-
tory test is performed for a final decision: HIV detection
is positive with a positive confirmatory test result, and
HIV detection is negative with a negative confirmatory
test result.
According to previous literature [4, 5, 12, 31, 32],
demographic characteristics (age, gender, race/ethnicity),
socio-economic status (poverty index, health insurance,
healthcare access, education), sexual activity (number of
sexual partners in the past year, sexual identity), and
drug use behaviors (number of drugs used, IDU, number
of times methamphetamine used in lifetime, age started
using methamphetamine) were known factors associated
with infection of BBV. Therefore, these variables were
included as potential confounders in the analyses.
Demographics (age, gender, and race), health insur-
ance, hospital utilization, and access to care information
were collected through Sample Person Questionnaire.
Socio-economic status (poverty index, education) was
obtained through Family Questionnaire. Drug use infor-
mation (e.g., number of drugs used, IDU, number of
times methamphetamine used in lifetime, and age
started using methamphetamine, etc.) was obtained
through Audio Computer Assisted Personal Self Inter-
view (ACASI) Questionnaire. Sexual behaviors (number
of sexual partners, sexual identity) were collected
through both ACASI and computer assisted personal
interview (CAPI) questionnaires during participants’ visit
to the examination center. All three BBV-related mea-
sures were obtained from corresponding laboratory tests.
The specific laboratory methods can be found elsewhere
[25]. Responses to questions including education, drug
use, and sexual activity were limited to participants aged
20 to 59 years.
Statistical analysis
Descriptive analyses include both crude and weighted
frequency and percentages of all covariates mentioned
above. The appropriate sample weights for combined
NHANES 2007–2016 data were constructed using Na-
tional Center for Health Statistics guidelines [33].
Weighted frequencies and percentages were calculated
by multiplying the sample weight WTMEC2YR by 0.2.
WTMEC2YR is the full sample two year MEC exam
weight, which indicates the weighted variable for labora-
tory measurements. We chose WTMEC2YR as the ap-
propriate weight in our analysis as WTMEC2YR has the
least common denominator. The Rao Scott Chi-squared
statistic was calculated to assess the association between
each covariate and outcome measure. Bivariate logistic
regression and three multivariable logistic regression
models were developed to examine the risk factors asso-
ciated with BBV positive results among people who used
methamphetamine. The outcome was tested positive for
BBV or negative to BBV as identified from laboratory
tests. The main risk factors of interest were drug use be-
haviors (number of drugs used, IDU, number of times
methamphetamine used in lifetime, and age started
using methamphetamine).
Model I, which only includes demographics, evaluated
the effect of demographic characteristics on the BBV
positive results. Model II further added a set of socio-
economic characteristics and sexual behavior informa-
tion into the modelling to evaluate their effect on the
BBV positive results, controlling for demographics. Al-
though health insurance, healthcare access, and number
of sexual partners were not statistically significant in our
model, they are, in general, confirmed risk factors for
BBV infection according to previous literatures, and they
were included in the model to adjust for their effects.
Model III further explored how drug use affects the BBV
positive results while taking into consideration all previ-
ous variables, which is our key research interest. The ra-
tionale to include them are two-fold: i), they are
statistically significantly associated (p < 0.05) with the
BBV positive results in the unadjusted analyses; ii), they
are suggested to have influence on the likelihood of a
positive BBV test.
Unadjusted odds ratios (uORs) and their 95% confi-
dence intervals (CIs) were reported from bivariate logis-
tic regression models, and adjusted odds ratios (aORs)
and their 95% CIs were reported from the three multi-
variable logistic regression models. Missing data were
not included in the modelling. For all ORs reported,
statistical significance was considered as CI not crossing
1 and corresponding p-value being less than 0.05. Chi-
square goodness-of-fit test was used to assess the devi-
ance between the statistical models.
R programming (RStudio, version 3.6) was used for all
analyses. Library “tidyverse” was used to clean data and
generate appropriate subsets for statistical analyses. Li-
brary “survey” and “srvyr” were used to analyze weighted
NHANES data. Survey functions “svytotal”, “svymean”,
“svychisq” and “svyCreateTableOne” were used to per-
form descriptive analyses; “svyglm” was used to perform
logistic regression modeling, and “jtools” was used to
draw Fig. 2.
Cai et al. BMC Infectious Diseases          (2020) 20:742 Page 4 of 11
Results
Overall 50,588 people participated in NHANES surveys
from 2007 to 2016, of whom 1878 participants who
failed to complete medical exams. Further, 29,894 partic-
ipants who were younger than 20 or over 59 years of age
were excluded. There were 18,816 participants eligible to
answer the question “ever using cocaine, heroin, or
methamphetamine” of whom 2491 (13.2%) participants
did not respond to this question. Participants with miss-
ing responses were more likely to be female (59% vs.
50%, p < 0.001) and belonging to races identified other
than white or black (48% vs. 39%, p < 0.001). There were
1132 participants who reported ever using metham-
phetamine constitute the final analytic sample (Fig. 1),
among whom 125 (11%) were BBV positive and 1007
(89%) were BBV negative. Specifically, 213 had HBV
vaccine-induced immunity. Among the 125 persons BBV
positive, the number of participants infected by HBV,
HCV, and HIV were 71 (57%), 78 (62%), and 11 (9%), re-
spectively. Additionally, 35 of them were infected by two
viruses: 6 were infected by both HIV and HBV, 29 were
infected by both HBV and HCV, and no one was in-
fected by both HCV and HIV. Table 1 summarizes the
crude and weighted numbers and percentages of the
characteristics of people who used methamphetamine.
Based on the weighted estimates, the 1132 participants
represented approximately 11,996,319 persons who used
methamphetamine in the U.S. population with the over-
all BBV positive rate at 13.0 per 100,000. Specifically, the
positive rate of HBV, HCV and HIV were 6.4, 8.1 and
1.3 per 100,000, respectively.
In the study sample, slightly over a third (36%) of the
participants were female, about two thirds (64%) were
non-Hispanic white, 26% of the participants were 50 to
59 years old and they accounted for 51% of BBV positive.
Approximately, a quarter (26%) of the participants were
living below the poverty threshold and they accounted
for 40% of BBV positive cases; another 29% were living
between 1 to 1.9 times poverty index and they accounted
for 31% of BBV positive cases. Over a third (36%) of the
Fig. 2 Effect Size of Adjusted Odds Ratios from Three Logistic Regression Models
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Table 1 Crude and Weighted Numbers and Percentages of the Characteristics of People Who Used Methamphetamine







Number 1132 11,996,319 125 (11) 1,298,339 (11) 1007 (89) 10,697,980 (89)
Gender 0.457
Female 406 (36) 4,187,779 (35) 43 (34) 398,993 (31) 363 (36) 3,788,786 (35)
Age < 0.001
20–29 years 187 (17) 1,779,073 (15) 4 (3) 68,424 (5) 183 (18) 1,710,649 (16)
30–39 years 319 (28) 2,968,405 (25) 22 (18) 162,889 (13) 297 (29) 2,805,516 (26)
40–49 years 330 (29) 3,554,951 (30) 35 (28) 405,851 (31) 295 (29) 3,149,100 (29)
50–59 years 296 (26) 3,693,889 (31) 64 (51) 661,174 (51) 232 (23) 3,032,716 (28)
Race 0.068
Non-Hispanic White 724 (64) 9,381,391 (78) 81 (65) 1,042,032 (80) 643 (64) 8,339,359 (78)
Non-Hispanic Black 65 (6) 322,951 (3) 14 (11) 65,729 (5) 51 (5) 257,221 (2)
Hispanic/Other 343 (30) 2,291,977 (19) 30 (24) 190,577 (15) 313 (31) 2,101,400 (20)
Poverty index 0.001
> =2 460 (41) 6,853,711 (57) 26 (21) 454,186 (38) 434 (43) 6,399,526 (62)
1 to 1.9 325 (29) 2,749,419 (23) 39 (31) 392,263 (33) 286 (28) 2,357,156 (23)
Below threshold 289 (26) 1,902,201 (16) 50 (40) 351,510 (29) 239 (24) 1,550,691 (15)
Missing 58 (5) 490,988 (4) 10 (8) 100,380 (8) 48 (5) 390,608 (4)
Health insurance 0.260
No 409 (36) 3,532,006 (29) 50 (40) 451,655 (35) 359 (36) 3,080,350 (29)
Healthcare access 0.353
No 277 (24) 2,606,354 (22) 30 (24) 331,797 (26) 247 (25) 2,274,556 (21)
Education 0.007
< 12 High School 259 (23) 2,059,325 (17) 39 (31) 385,837 (30) 220 (22) 1,673,488 (16)
Sexual partner 0.209
< 2 825 (73) 9,005,285 (75) 82 (66) 899,510 (69) 743 (74) 8,105,775 (76)
> =2 299 (26) 2,947,253 (25) 39 (31) 379,316 (29) 260 (26) 2,567,937 (24)
Missing 8 (1) 43,782 (0) 4 (3) 19,513 (2) 4 (0) 24,269 (0)
Sexual identity 0.001
Heterosexual 1060 (94) 11,287,813 (94) 106 (85) 1,081,527 (83) 954 (95) 10,206,286 (95)
Other 70 (6) 697,104 (6) 18 (14) 210,072 (16) 52 (5) 487,032 (5)
Missing 2 (0) 11,402 (0) 1 (1) 6740 (1) 1 (0) 4662 (0)
Number of drug use < 0.001
1 (only methamphetamine) 97 (9) 856,452 (7) 7 (6) 40,539 (3) 90 (9) 815,912 (8)
2 (methamphetamine +
heroin or cocaine)
828 (73) 9,139,692 (76) 57 (46) 728,512 (56) 771 (77) 8,411,180 (79)
3 (methamphetamine +
heroin and cocaine)
207 (18) 2,000,175 (17) 61 (49) 529,288 (41) 146 (14) 1,470,888 (14)
Injection drug use < 0.001
Yes 243 (21) 2,534,473 (21) 80 (64) 701,223 (54) 163 (16) 1,833,250 (17)
Missing 1 (0) 7107 (0) 1 (1) 7107 (1) 0 (0) 0 (0)
Number of times use drug 0.014
< =5 times 352 (31) 3,938,546 (33) 25 (20) 273,084 (21) 327 (32) 3,665,462 (34)
6–49 times 381 (34) 4,192,770 (35) 36 (29) 406,771 (31) 345 (34) 3,785,998 (35)
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participants did not have any health insurance, and
nearly a quarter (24%) did not have routine healthcare
access. Nearly a third (31%) of the BBV positive partici-
pants had less than high school education. The 6% of
participants whose sexual identity was identified as other
than heterosexual were accounted for 14% of BBV posi-
tive cases. While only 18% of people who used metham-
phetamine also reported ever using the other two drugs
(heroin and cocaine), they accounted for almost a half
(49%) of BBV positive cases. The majority of people who
used methamphetamine did not inject any drugs (79%);
however, almost two thirds (64%) of BBV positive were
among the 21% persons with IDU. Over half (51%) of
the participants first started using methamphetamine at
age 18 to 25, about a quarter (26%) between 10 and 17
years, and another quarter (23%) older than 25 years.
Table 2 summarizes the estimated model effects (uOR
and aOR with 95% CIs) of factors associated with the
outcome variable. The three multivariable logistic re-
gression models adjusted for the covariates in a stepwise
manner. The effect size of all aORs with 95% CIs are il-
lustrated in Fig. 2. In model 1, only being older than 50
(vs. age 20–29, 5.31; 1.54–18.24) was significantly associ-
ated with BBV positive cases. After adding socio-
economic status and sexual activities into model 2, there
were significant associations of BBV positive with age
40–49 years old (vs. age 20–29, 5.64; 1.41–22.62), age
50–59 years old (vs. age 20–29, 13.09; 3.21–53.43), living
around poverty index 1 to 1.9 (vs. living 2 times above
poverty index, 2.93; 1.44–5.98), living below the poverty
threshold (vs. living 2 times above poverty index, 3.68;
1.48–9.17), having lower than high school education (vs.
equal to or higher than high school education, 2.95;
1.44–6.05), having more than one sexual partner (vs.
having less than two sexual partners, 1.84; 1.09–3.11),
and sex identity other than heterosexual (vs. heterosex-
ual, 4.53; 1.78–11.55). In the model 3, after adding drug
use behaviors, associations of the same risk factors with
BBV positive persisted: age 40–49 years old (vs. age 20–
29, 4.77; 1.11–20.55), age 50–59 years old (vs. age 20–29,
10.25; 2.40–43.82), living around poverty index 1 to 1.9
(vs. living 2 times above poverty index, 2.55; 1.19–5.49),
living below the poverty threshold (vs. living 2 times
above poverty index, 2.55; 1.11–5.86), having lower than
high school education (vs. equal to or higher than high
school education, 3.13; 1.51–6.46), and sexual identity
other than heterosexual (vs. heterosexual, 5.60; 1.72–
18.28). In addition, in this model, people who used her-
oin and cocaine (vs. never used heroin or cocaine, 4.24;
1.06–16.92), IDU (vs. no IDU, 3.15; 1.61–6.16), and
started using methamphetamine at ages over 25 (vs.
started using methamphetamine between age 10 to 17,
2.09; 1.01–4.35) were also significantly associated with
BBV positive. The chi-square goodness-of-fit test sug-
gests that there is no evidence of severe overfitting on
the modeling.
Discussion
Findings from our study using 10 consecutive years of
NHANES data suggest that polysubstance use and IDU
were strongly associated with increased risk of being
BBV positive among people who used methampheta-
mine. Compared with people who were tested BBV
negative, those tested BBV positive were largely older,
living two times below the poverty index, holding less
than a high school education, possessing a sexual iden-
tity other than heterosexual, having ever used all three
illicit drugs including methamphetamine, heroin, and co-
caine, having ever injected drugs, and having started
using methamphetamine at ages over 25. Previous litera-
ture has shown that people who use methamphetamine
have an elevated risk of BBVs infection through sexual
risk and injecting risk [9, 34, 35]. Our study found that
injection drug use and sexual identity other than hetero-
sexual are significant risk factors associated with ele-
vated risk of BBV infection among this population.
Studies examining polysubstance use and their associa-
tions with harmful health effects are usually conducted
Table 1 Crude and Weighted Numbers and Percentages of the Characteristics of People Who Used Methamphetamine (Continued)







> =50 times 396 (35) 3,848,774 (32) 63 (50) 613,979 (47) 333 (33) 3,234,794 (30)




10–17 years 291 (26) 3,193,550 (27) 33 (26) 319,933 (25) 258 (26) 2,873,617 (27)
18–25 years 576 (51) 6,382,330 (53) 50 (40) 503,483 (39) 526 (52) 5,878,847 (55)
> =26 years 261 (23) 2,399,476 (20) 42 (34) 474,923 (37) 219 (22) 1,924,553 (18)
Missing 4 (0) 20,963 (0) 0 (0) 0 (0) 4 (0) 20,963 (0)
a P value for Rao-Scott χ2 test statistic, significance was denoted in bold
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Table 2 Unadjusted and Adjusted Odds Ratios for Associations between Risk Factors and Blood-borne Viruses’ Positive Results
Model 1 Model 2 Model 3
Variable uOR [95% CI] aOR [95% CI] aOR [95% CI] aOR [95% CI]
Gender
Male# 1 1 1 1
Female 0.81 [0.46, 1.41] 0.82 [0.47, 1.42] 0.86 [0.45, 1.63] 0.93 [0.45, 1.95]
Age
20–29 years# 1 1 1 1
30–39 years 1.45 [0.50, 4.20] 1.44 [0.49, 4.23] 2.01 [0.60, 6.75] 1.58 [0.42, 5.99]
40–49 years 3.22 * [1.02, 10.16] 3.19 [0.98, 10.36] 5.64 * [1.41, 22.62] 4.77 * [1.11, 20.55]
50–59 years 5.45 ** [1.63, 18.26] 5.31 * [1.54, 18.24] 13.09 *** [3.21, 53.43] 10.25 ** [2.40, 43.82]
Race
Non-Hispanic White# 1 1 1 1
Non-Hispanic Black 2.05 * [1.06, 3.95] 1.88 [0.98, 3.62] 0.84 [0.32, 2.24] 0.77 [0.25, 2.34]
Hispanic/Other 0.73 [0.43, 1.24] 0.95 [0.55, 1.63] 0.66 [0.37, 1.19] 0.74 [0.37, 1.46]
Poverty index
> =2# 1 1 1
1 to 1.9 2.34 ** [1.29, 4.27] 2.93 ** [1.44, 5.98] 2.55 * [1.19, 5.49]
Below threshold 3.19 ** [1.62, 6.29] 3.68 ** [1.48, 9.17] 2.55 * [1.11, 5.86]
Health Insurance
Yes# 1 1 1
No 1.32 [0.82, 2.13] 1.16 [0.65, 2.07] 1.00 [0.52, 1.92]
Healthcare access
Yes# 1 1 1
No 1.27 [0.77, 2.11] 1.17 [0.71, 1.93] 1.11 [0.63, 1.95]
Education
> =12 H.S. or GED# 1 1 1
< 12 H.S. 2.28 ** [1.27, 4.11] 2.95 ** [1.44, 6.05] 3.13 ** [1.51, 6.46]
Number of sexual partners
< 2# 1 1 1
> =2 1.33 [0.85, 2.07] 1.84 * [1.09, 3.11] 1.41 [0.78, 2.54]
Sexual identity
Heterosexual# 1 1 1
Other 4.07 ** [1.71, 9.68] 4.53 ** [1.78, 11.55] 5.60 ** [1.72, 18.28]
Number of drug use
1 [only methamphetamine]# 1 1
2 [methamphetamine + heroin or cocaine] 1.74 [0.75, 4.07] 1.69 [0.53, 5.41]
3 [methamphetamine + heroin and cocaine] 7.24 *** [2.93, 17.89] 4.24 * [1.06, 16.92]
Injection drug use
No# 1 1
Yes 5.75 *** [3.40, 9.70] 3.15 ** [1.61, 6.16]
Number of times use drug
< =5 times# 1 1
6–49 times 1.44 [0.71, 2.94] 1.09 [0.47, 2.52]
> =50 times 2.55 ** [1.29, 5.02] 1.29 [0.53, 3.14]
Age started using methamphetamine
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at a smaller scale and among high-risk populations be-
cause of the challenges in capturing such information
[19]. Using latent class analysis, studies have illustrated
greater occurrences of sexual risk behaviors and in-
creased diagnoses of blood-borne infections [36]. Find-
ings from our study using nationally representative
sample with large sample size corroborate results from
previous smaller studies that individuals with polysub-
stance use (i.e., co-ingestion or sequential use of meth-
amphetamine with heroin, fentanyl, or cocaine) have a
higher likelihood of being tested BBV positive.
Our study results suggest that persons who started
using methamphetamine at ages over 25 were more
likely to be tested BBV positive, compared to those who
started using methamphetamine at an early age. In a
study assessing the effect of age and HIV status on
methamphetamine use, the authors conclude that older
persons without HIV were using methamphetamine at
higher levels and were, therefore, at an increased risk of
HIV [11]. More informed knowledge about risky behav-
iors among vulnerable age-groups can provide guidance
to tailor treatment among this subgroup of population.
A recent study concluded that women using metham-
phetamine were four times more likely to be infected by
HBV compared to males [12]. While our study did not
find sex statistically significantly associated with BBV
positive results, the odds ratio did indicate that women
are more likely to be exposed to HBV compared to men.
Similarly, the number of past year sexual partners is also
likely associated with elevated risk of being tested BBV
positive, although not statistically significant.
There are potential limitations associated with this
study. Firstly, NHANES participants do not include incar-
cerated or homeless individuals, who have a higher rate of
methamphetamine use than general population. This may
affect the generalizability of our conclusion to the entire
US adult population. Secondly, for sexual identity, we
coded any heterosexual as “heterosexual”, and left all the
others as “other than heterosexual”, including men who
had sex with men (MSM), female homosexuals, and other
sexual identities. Although previous literature has identi-
fied MSM as a known risk factor for BBV infection, due to
the small sample size of this group (n = 26, less than 3%),
we categorized MSM into “other than heterosexual”. This
recoding method may be different from others and affect
the generalizability of our results. Thirdly, questions about
illicit drug use and sexual behavior are sensitive in nature,
thus, people might refuse to respond or be unwilling to re-
spond honestly to those questions, leading to incorrect es-
timates. Fourthly, some subgroups have very small sample
sizes and therefore, very large confidence intervals. The
small sample size potentially limited the power of our
study. We had carefully categorized risk factors associated
with BBV infection and reduced the effect of the small
sample size. Fifthly, we have used “lifetime use of metham-
phetamine” instead of “most recent use of methampheta-
mine” as the key case selection variable. The reason is that
only 15.8% of the participants in our study reported using
methamphetamine in the last year. We recognize that the
response to the question of lifetime use of methampheta-
mine might not be associated with BBV infection tempor-
ally. For one, the methamphetamine use could have been
many years before any risk for blood-borne infection; for
another, the use of methamphetamine could have com-
menced after the BBV infection.
Conclusions
In conclusion, as methamphetamine use, especially poly-
substance use including methamphetamine, continues to
increase, it is of great public health importance to iden-
tify those vulnerable populations who are prone to be
infected by BBVs. The results of the study are expected
to provide evidence to inform timely harm reduction ef-
forts to identify this population and target vaccination
and interventions to prevent transmission. Prevention
and intervention efforts targeted toward these specific
subgroups, including people who use poly-substances,
people who inject methamphetamine and/or other sub-
stances, people living in low social-economic status, and
minorities in sexual identification, can help alleviate fatal
and nonfatal harms caused by methamphetamine use. In
addition, an evolving polysubstance use landscape indi-
cates a need for a rapid, multifaceted approach to in-
corporate more comprehensive surveillance efforts to
inform effective prevention and response strategies to
prevent blood-borne infection outbreaks.
Table 2 Unadjusted and Adjusted Odds Ratios for Associations between Risk Factors and Blood-borne Viruses’ Positive Results
(Continued)
Model 1 Model 2 Model 3
Variable uOR [95% CI] aOR [95% CI] aOR [95% CI] aOR [95% CI]
10–17 years# 1 1
18–25 years 0.77 [0.39, 1.51] 0.99 [0.44, 2.24]
> =26 years 2.22 ** [1.26, 3.91] 2.09 * [1.01, 4.35]
Abbreviations: uOR unadjusted odds ratio, aOR adjusted odds ratio, HS high school, GED General Education Development
1. # indicates reference category
2. Statistical significance: *** p < 0.001; ** p < 0.01; * p < 0.05
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